Palvella Therapeutics (PVLA) vs Trevi Therapeutics (TRVI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Palvella Therapeutics (PVLA) has outperformed Trevi Therapeutics (TRVI) over the past year, gaining 75.5% versus a gain of 30.6%. Over five years, TRVI leads with a +894.2% price change compared with -63.6% for PVLA. Palvella Therapeutics is the larger company by market cap ($1.89 billion vs $1.83 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PVLA | TRVI |
|---|---|---|
| Share price | $131.34 | $12.83 |
| Market cap | $1.89B | $1.83B |
| 1-day change | +0.57% | -2.40% |
| YTD return | +25.48% | +2.44% |
| 1-year return | +75.47% | +30.60% |
| 5-year return | -63.60% | +894.19% |
| EPS (TTM) | $-4.85 | $-0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-41.72M | $-42.76M |
| 52-week high | $161.38 | $20.22 |
| 52-week low | $65.93 | $9.28 |
| Distance from 52-week high | -18.61% | -36.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +75.52% | +119.73% |
| Average volume | 211.36K | 1.95M |
| Shares outstanding | 14.41M | 142.48M |
| Employees | 29 | 34 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PVLA has outperformed TRVI by 44.9 percentage points over the past year.
About Palvella Therapeutics
PVLA stock →Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About Trevi Therapeutics
TRVI stock →Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company develops Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF, and phase 2a clinical trial in patients with refractory chronic cough.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
PVLA vs TRVI FAQ
Which is bigger, Palvella Therapeutics or Trevi Therapeutics?
Palvella Therapeutics (PVLA) is larger, with a market capitalization of $1.89B compared with $1.83B for Trevi Therapeutics (TRVI).
Which stock has performed better over the past year, PVLA or TRVI?
PVLA returned +75.47% over the past 12 months, compared with +30.60% for TRVI (price return, excluding dividends). Past performance does not predict future results.
Are Palvella Therapeutics and Trevi Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.